^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | losatuxizumab vedotin (ABBV-221) (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Excerpt:
ABBV-221 has similar activity as depatux-m against an EGFR-amplified GBM patient derived xenograft (PDX) model and is highly effective alone and in combination with standard-of-care temozolomide in an EGFRvIII-positive GBM xenograft model.
DOI:
10.1158/1535-7163.MCT-17-0710
